An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.

Trial Details

NCT ID
NCT06083870
Phase
PHASE1
Sponsor
Lu Shun
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Oba01
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntary agreement to provide written informed consent.
  • Man or woman ≥ 18 years and ≤75 years of age at the time of enrollment.
  • Histologically and/or cytologically-confirmed locally advanced or metastatic NSCLC.
  • Measurable lesion according to RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →